Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMEC - Durvalumab and Olaparib in recurrent/metastatic endometrial cancer
2018-004575-12Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and olaparib in endometrial cancer (EC), sponsored by Leiden University Medical Center. Primary endpoint: Progression-free survival (median). Started Jul 2019; status: active.
02
Drugs
durvalumabolaparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2018-004575-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004575-12.